ROIVANT SCIENCES LTD. Restricted Cash
ROIVANT SCIENCES LTD. (ROIV) had Restricted Cash of $13.63 million as of 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Balance Sheet › Assets › Restricted Cash and Investments
us-gaap:RestrictedCash · last filed 2022-11-14
- 2022-09-30: Restricted Cash $13.63M.
- 2022-06-30: Restricted Cash $14.25M.
- 2022-03-31: Restricted Cash $13.63M.
- 2021-12-31: Restricted Cash $11.85M.
| Period end | Restricted Cash |
|---|---|
| 2022-09-30 | $13.63M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $14.25M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $13.63M 10-Q · filed 2022-11-14 |
| 2021-12-31 | $11.85M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $11.79M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $11.64M 10-Q · filed 2021-09-21 |
| 2021-03-31 | $86.63M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |